Novo Nordisk Obesity Drug Wins FDA Panel Support

September 16, 2014 | by

Last week Thursday, an FDA advisory panel recommended the approval of Novo Nordisk’s injectable drug liraglutide for the treatment of obesity.

Liraglutide